Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Gross Margin (2022 - 2025)

Atara Biotherapeutics' Gross Margin history spans 4 years, with the latest figure at 93.48% for Q4 2025.

  • For Q4 2025, Gross Margin rose 1423.0% year-over-year to 93.48%; the TTM value through Dec 2025 reached 82.44%, down 127.0%, while the annual FY2025 figure was 82.44%, 127.0% down from the prior year.
  • Gross Margin reached 93.48% in Q4 2025 per ATRA's latest filing, down from 96.67% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q1 2022 to a low of 265.07% in Q2 2023.
  • Average Gross Margin over 4 years is 57.24%, with a median of 88.29% recorded in 2024.
  • Peak YoY movement for Gross Margin: tumbled -36507bps in 2023, then skyrocketed 34891bps in 2024.
  • A 4-year view of Gross Margin shows it stood at 100.0% in 2022, then crashed by -75bps to 24.56% in 2023, then soared by 223bps to 79.25% in 2024, then rose by 18bps to 93.48% in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Gross Margin are 93.48% (Q4 2025), 96.67% (Q3 2025), and 96.85% (Q2 2025).